Header Logo

Connection

Shan Lu to Humans

This is a "connection" page, showing publications Shan Lu has written about Humans.
Connection Strength

0.577
  1. Wang S, Chan KW, Wei D, Ma X, Liu S, Hu G, Park S, Pan R, Gu Y, Nazzari AF, Olia AS, Xu K, Lin BC, Louder MK, McKee K, Doria-Rose NA, Montefiori D, Seaman MS, Zhou T, Kwong PD, Arthos J, Kong XP, Lu S. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains. Nat Commun. 2024 May 21; 15(1):4301.
    View in: PubMed
    Score: 0.035
  2. Li H, Wang S, Hu G, Zhang L, Liu S, Lu S. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. Emerg Microbes Infect. 2021 Dec; 10(1):833-841.
    View in: PubMed
    Score: 0.030
  3. Wang S, Voronin Y, Zhao P, Ishihara M, Mehta N, Porterfield M, Chen Y, Bartley C, Hu G, Han D, Wells L, Tiemeyer M, Lu S. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions. J Virol. 2020 03 17; 94(7).
    View in: PubMed
    Score: 0.026
  4. Lu S. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect. 2020; 9(1):542-544.
    View in: PubMed
    Score: 0.026
  5. Flotte TR, Lu S. DNA Vaccination in 2018: An Update. Hum Gene Ther. 2018 09; 29(9):963-965.
    View in: PubMed
    Score: 0.024
  6. Suschak JJ, Wang S, Fitzgerald KA, Lu S. Identification of Aim2 as a sensor for DNA vaccines. J Immunol. 2015 Jan 15; 194(2):630-6.
    View in: PubMed
    Score: 0.018
  7. Haran JP, Hoaglin DC, Chen H, Boyer EW, Lu S. Antigen-specific H1N1 influenza antibody responses in acute respiratory tract infections and their relation to influenza infection and disease course. J Clin Virol. 2014 Aug; 60(4):367-73.
    View in: PubMed
    Score: 0.018
  8. Lu S. Editorial overview: vaccines against challenging viral pathogens and new vaccine technology. Curr Opin Virol. 2014 Jun; 6:viii-ix.
    View in: PubMed
    Score: 0.018
  9. Lu S. Novel vaccine technology and the future of vaccine science. Hum Vaccin Immunother. 2014; 10(5):1143-6.
    View in: PubMed
    Score: 0.017
  10. Wang S, Lu S. DNA immunization. Curr Protoc Microbiol. 2013 Nov 05; 31:18.3.1-18.3.24.
    View in: PubMed
    Score: 0.017
  11. Haran JP, Buglione-Corbett R, Lu S. Cytokine markers as predictors of type of respiratory infection in patients during the influenza season. Am J Emerg Med. 2013 May; 31(5):816-21.
    View in: PubMed
    Score: 0.016
  12. Wang S, Kishko M, Wan S, Wang Y, Brewster F, Gray GE, Violari A, Sullivan JL, Somasundaran M, Luzuriaga K, Lu S. Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates. Hum Vaccin Immunother. 2012 Nov 01; 8(11):1638-47.
    View in: PubMed
    Score: 0.016
  13. Haran JP, Beaudoin FL, Suner S, Lu S. C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness. Am J Emerg Med. 2013 Jan; 31(1):137-44.
    View in: PubMed
    Score: 0.016
  14. Lu S. Two is better than one. Lancet Infect Dis. 2011 Dec; 11(12):889-91.
    View in: PubMed
    Score: 0.015
  15. Clapham PR, Lu S. Vaccinology: precisely tuned antibodies nab HIV. Nature. 2011 Sep 21; 477(7365):416-7.
    View in: PubMed
    Score: 0.015
  16. Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol. 2011 May; 85(10):4927-36.
    View in: PubMed
    Score: 0.014
  17. Lu S, Grimes Serrano JM, Wang S. Polyvalent AIDS vaccines. Curr HIV Res. 2010 Dec; 8(8):622-9.
    View in: PubMed
    Score: 0.014
  18. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One. 2010 Nov 09; 5(11):e13916.
    View in: PubMed
    Score: 0.014
  19. Lu S, Wang S. Technical transformation of biodefense vaccines. Vaccine. 2009 Nov 05; 27 Suppl 4:D8-D15.
    View in: PubMed
    Score: 0.013
  20. Lu S. Gene-based adjuvants: a new meaning. Hum Gene Ther. 2009 Oct; 20(10):1101-2.
    View in: PubMed
    Score: 0.013
  21. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009 Jun; 21(3):346-51.
    View in: PubMed
    Score: 0.012
  22. Lu S. Immunogenicity of DNA vaccines in humans: it takes two to tango. Hum Vaccin. 2008 Nov-Dec; 4(6):449-52.
    View in: PubMed
    Score: 0.012
  23. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Jul 23; 26(31):3947-57.
    View in: PubMed
    Score: 0.012
  24. Wang S, Parker C, Taaffe J, Sol?rzano A, Garc?a-Sastre A, Lu S. Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008 Jul 04; 26(29-30):3626-33.
    View in: PubMed
    Score: 0.012
  25. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines. 2008 Mar; 7(2):175-91.
    View in: PubMed
    Score: 0.011
  26. Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, Arthos J, Pal R, Markham P, Lu S. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008 Feb 20; 26(8):1098-110.
    View in: PubMed
    Score: 0.011
  27. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology. 2008 Feb 05; 371(1):98-107.
    View in: PubMed
    Score: 0.011
  28. Shen S, Wang S, Britt WJ, Lu S. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Vaccine. 2007 Apr 30; 25(17):3319-27.
    View in: PubMed
    Score: 0.011
  29. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol. 2006 Nov; 28(3):255-65.
    View in: PubMed
    Score: 0.010
  30. Wang S, Taaffe J, Parker C, Sol?rzano A, Cao H, Garc?a-Sastre A, Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol. 2006 Dec; 80(23):11628-37.
    View in: PubMed
    Score: 0.010
  31. Biswas S, Langeveld JP, Tipper D, Lu S. Intracellular accumulation of a 46 kDa species of mouse prion protein as a result of loss of glycosylation in cultured mammalian cells. Biochem Biophys Res Commun. 2006 Oct 13; 349(1):153-61.
    View in: PubMed
    Score: 0.010
  32. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005 Jun; 79(12):7933-7.
    View in: PubMed
    Score: 0.009
  33. Chou TH, Wang S, Sakhatskyy PV, Mboudjeka I, Mboudoudjeck I, Lawrence JM, Huang S, Coley S, Yang B, Li J, Zhu Q, Lu S. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2005 Mar 30; 334(1):134-43.
    View in: PubMed
    Score: 0.009
  34. Wang S, Chou TH, Sakhatskyy PV, Huang S, Lawrence JM, Cao H, Huang X, Lu S. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005 Feb; 79(3):1906-10.
    View in: PubMed
    Score: 0.009
  35. Chou TH, Biswas S, Lu S. Gene delivery using physical methods: an overview. Methods Mol Biol. 2004; 245:147-66.
    View in: PubMed
    Score: 0.009
  36. Quitadamo B, Peters PJ, Repik A, O'Connell O, Mou Z, Koch M, Somasundaran M, Brody R, Luzuriaga K, Wallace A, Wang S, Lu S, McCauley S, Luban J, Duenas-Decamp M, Gonzalez-Perez MP, Clapham PR. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded. J Virol. 2018 01 15; 92(2).
    View in: PubMed
    Score: 0.006
  37. Costa MR, Pollara J, Edwards RW, Seaman MS, Gorny MK, Montefiori DC, Liao HX, Ferrari G, Lu S, Wang S. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. J Virol. 2016 Nov 15; 90(22):10362-10378.
    View in: PubMed
    Score: 0.005
  38. Haran JP, Hayward G, Skinner S, Merritt C, Hoaglin DC, Hibberd PL, Lu S, Boyer EW. Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics. Am J Emerg Med. 2014 Oct; 32(10):1195-9.
    View in: PubMed
    Score: 0.004
  39. E X, Savidis G, Chin CR, Wang S, Lu S, Brass AL, Kowalik TF. A novel DDB2-ATM feedback loop regulates human cytomegalovirus replication. J Virol. 2014 Feb; 88(4):2279-90.
    View in: PubMed
    Score: 0.004
  40. O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, Duenas-Decamp M, Peters P, Lin R, Zolla-Pazner S, Corti D, Wallace A, Wang S, Kong XP, Lu S, Clapham PR. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. J Virol. 2013 Jan; 87(1):187-98.
    View in: PubMed
    Score: 0.004
  41. Xiaofei E, Stadler BM, Debatis M, Wang S, Lu S, Kowalik TF. RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions. J Virol. 2012 May; 86(10):5660-73.
    View in: PubMed
    Score: 0.004
  42. E X, Pickering MT, Debatis M, Castillo J, Lagadinos A, Wang S, Lu S, Kowalik TF. An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus. PLoS Pathog. 2011 May; 7(5):e1001342.
    View in: PubMed
    Score: 0.004
  43. Wang Z, Zhang M, Wang Y, Jiao Y, Zhang L, Li L, Huang Z, Wu H, Li J, Lu S, Wang S. A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. J Virol Methods. 2011 Jan; 171(1):183-9.
    View in: PubMed
    Score: 0.003
  44. Vaine M, Lu S, Wang S. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs. 2009; 23(3):137-53.
    View in: PubMed
    Score: 0.003
  45. Kennedy JS, Co M, Green S, Longtine K, Longtine J, O'Neill MA, Adams JP, Rothman AL, Yu Q, Johnson-Leva R, Pal R, Wang S, Lu S, Markham P. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine. 2008 Aug 18; 26(35):4420-4.
    View in: PubMed
    Score: 0.003
  46. Pouliot K, Pan N, Wang S, Lu S, Lien E, Goguen JD. Evaluation of the role of LcrV-Toll-like receptor 2-mediated immunomodulation in the virulence of Yersinia pestis. Infect Immun. 2007 Jul; 75(7):3571-80.
    View in: PubMed
    Score: 0.003
  47. Abdel-Motal U, Wang S, Lu S, Wigglesworth K, Galili U. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol. 2006 Jul; 80(14):6943-51.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.